Enhancing tumor cell response to chemotherapy through nanoparticle-mediated codelivery of siRNA and cisplatin prodrug. - Wikidata - wikimedia - TriplyDB

Enhancing tumor cell response to chemotherapy through nanoparticle-mediated codelivery of siRNA and cisplatin prodrug.

Enhancing tumor cell response to chemotherapy through nanoparticle-mediated codelivery of siRNA and cisplatin prodrug.

http://www.wikidata.org/entity/Q37319709

about

Nanodiamonds: The intersection of nanotechnology, drug development, and personalized medicine Cancer nanomedicine: from targeted delivery to combination therapy Targeting cancer cells in the tumor microenvironment: opportunities and challenges in combinatorial nanomedicine.Ancient genes establish stress-induced mutation as a hallmark of cancer A DNA dual lock-and-key strategy for cell-subtype-specific siRNA delivery.Surface De-PEGylation Controls Nanoparticle-Mediated siRNA Delivery In Vitro and In Vivo.Pt(IV) prodrugs designed to bind non-covalently to human serum albumin for drug delivery Cisplatin modulates B-cell translocation gene 2 to attenuate cell proliferation of prostate carcinoma cells in both p53-dependent and p53-independent pathways.Progress in aptamer-mediated drug delivery vehicles for cancer targeting and its implications in addressing chemotherapeutic challenges.Nanomedicine in the Management of Microbial Infection - Overview and Perspectives Nanodiamond-mitoxantrone complexes enhance drug retention in chemoresistant breast cancer cells Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology.Nanoparticles with Precise Ratiometric Co-Loading and Co-Delivery of Gemcitabine Monophosphate and Cisplatin for Treatment of Bladder Cancer.Self-assembled nanoscale coordination polymers carrying siRNAs and cisplatin for effective treatment of resistant ovarian cancer.REV7 is essential for DNA damage tolerance via two REV3L binding sites in mammalian DNA polymerase ζ Starvation promotes REV1 SUMOylation and p53-dependent sensitization of melanoma and breast cancer cells.Crosstalk between translesion synthesis, Fanconi anemia network, and homologous recombination repair pathways in interstrand DNA crosslink repair and development of chemoresistance Long-circulating siRNA nanoparticles for validating Prohibitin1-targeted non-small cell lung cancer treatment.Cooperative Treatment of Metastatic Breast Cancer Using Host-Guest Nanoplatform Coloaded with Docetaxel and siRNA.The Polymerase Activity of Mammalian DNA Pol ζ Is Specifically Required for Cell and Embryonic Viability.Triple-Layered pH-Responsive Micelleplexes Loaded with siRNA and Cisplatin Prodrug for NF-Kappa B Targeted Treatment of Metastatic Breast Cancer.Tumour-associated macrophages act as a slow-release reservoir of nano-therapeutic Pt(IV) pro-drug.Nanodrug Formed by Coassembly of Dual Anticancer Drugs to Inhibit Cancer Cell Drug Resistance.Recent advances of cocktail chemotherapy by combination drug delivery systems.Combination Therapy for Ulcerative Colitis: Orally Targeted Nanoparticles Prevent Mucosal Damage and Relieve Inflammation.The influence of p53 mutation status on the anti-cancer effect of cisplatin in oral squamous cell carcinoma cell lines Breakthrough for a DNA break-preventer.Profile of Graham C. Walker.Nanotechnology in the management of cervical cancer.Polymeric 3D nano-architectures for transport and delivery of therapeutically relevant biomacromolecules.Nanocarriers for delivery of siRNA and co-delivery of siRNA and other therapeutic agents.Polymeric biomaterials for the delivery of platinum-based anticancer drugs.CCR 20th Anniversary Commentary: Prospects and Challenges of Therapeutic Nanoparticles in Cancer.Current views on inducing synthetic lethal RNAi responses in the treatment of cancer.Identification of Small Molecule Translesion Synthesis Inhibitors That Target the Rev1-CT/RIR Protein-Protein Interaction.Recent updates in utilizing prodrugs in drug delivery (2013-2015).A Multi-Mitochondrial Anticancer Agent that Selectively Kills Cancer Cells and Overcomes Drug Resistance.Nanoparticle formulations of cisplatin for cancer therapy.Prodrug-based nano-drug delivery system for co-encapsulate paclitaxel and carboplatin for lung cancer treatment.Nanocarrier-based co-delivery of small molecules and siRNA/miRNA for treatment of cancer.

P2860

Q26776095-347AA698-DA05-4FE0-975F-AB6603C311C4 Q28083065-923B5174-388B-415E-ACEB-0F659BF03485 Q30279055-481C6313-A50E-4C22-8ECE-4DFE85D8690E Q33602374-7C2C4421-240D-498D-89D3-4FCEC6C72183 Q33813408-407B247A-5062-4ED8-B193-75B07B6C284B Q33821050-F6C3B852-E462-4AFB-BBD0-9466E7A14712 Q33825880-9DECCBF2-E3B2-404A-9BEA-C2911260462C Q33827212-152B3A68-D810-4F35-9912-D25CA865FFB3 Q33935498-F0539B43-66B8-4E5A-84F5-B3E84B32599F Q34245494-047CC3D1-1001-4DA7-AFBE-3FE8BA504638 Q34435737-C7C4324D-8C2B-43CE-B478-A6264BED4266 Q34447986-B99F6CF7-604D-4B59-BBAC-67CACE676788 Q34479313-0E3042B5-9046-4EE5-9256-B38D4ED07C39 Q34617008-06595544-F79A-4592-A6E9-07A3344D4666 Q35098093-60E015C7-D8AD-407C-A1A4-BCAABB724467 Q35178418-FCF1A54B-2D84-4DD9-B5A5-36633F524455 Q35205030-F3AD42A7-0774-4122-A741-77F944978543 Q35796255-B9CA7EAD-7A24-4D6C-9E77-2082211DC68C Q35867861-DB04F611-0D09-4240-ADC7-8445F7DC9F03 Q35884176-B2CF6F57-908C-4B0C-9E71-F36DC6E427CA Q36372323-B0020A33-F01D-42E1-B688-6A5E2224DEB6 Q36459188-0CABC7A3-FC6A-47A2-8C82-9622B04C3DF6 Q36461811-0CE93DD2-9419-4951-BB7A-C9A2A01D1E23 Q37206908-6C810607-2014-42B9-90B0-6185DA8F6B95 Q37469872-030FA1E7-B155-455C-8713-1AB8AFD2A0E1 Q37549047-5835A401-8D15-4E28-8F4A-B38D8B8656D8 Q37612668-5462FE05-EBB2-47AA-A7C1-E2DA3EA86573 Q37628038-46B1DF51-918A-4E19-9C0A-CAA561170367 Q38370785-F75F3FED-1CE7-4C3E-B196-66799F2FF7CB Q38555019-0CF321E6-C909-4C1F-B461-07D9B7DE2F28 Q38555082-A486368E-40CF-4C32-939C-ADF2A8905670 Q38556758-999DFBBE-FACF-4D56-9465-6487BF58019D Q38608825-8058B2D6-6975-4D77-8F43-7252C2475EBA Q38656763-7DA61E23-C6EE-464E-B0FD-95B76D8763B7 Q38679334-41BDE2C1-90C3-435D-A17F-159637FC6168 Q38702949-668E6927-80BA-4E28-82A0-E144CDD9DB5C Q38720819-218B4D73-6D81-4BA5-9EB6-080A693BF68D Q38723829-960CC333-0DF8-49E8-9105-9B6340A1441E Q38741016-52F4AA2E-223E-411E-99DA-87C16D12DECF Q38787321-C5A70B56-18EC-402D-BFAF-7017527BA038

P2860

Enhancing tumor cell response to chemotherapy through nanoparticle-mediated codelivery of siRNA and cisplatin prodrug.

http://www.wikidata.org/entity/Q37319709

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 28 October 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Enhancing tumor cell response ...... f siRNA and cisplatin prodrug.

@en

Enhancing tumor cell response ...... f siRNA and cisplatin prodrug.

@nl

type

label

Enhancing tumor cell response ...... f siRNA and cisplatin prodrug.

@en

Enhancing tumor cell response ...... f siRNA and cisplatin prodrug.

@nl

prefLabel

Enhancing tumor cell response ...... f siRNA and cisplatin prodrug.

@en

Enhancing tumor cell response ...... f siRNA and cisplatin prodrug.

@nl

P1433

Q37319709-13D89D01-ACD3-4442-A88D-9E55383BCE54

P1476

Q37319709-CB851DCF-DEAC-4AB3-BB66-BC83FF3437AC

P2093

Q37319709-023160E4-20D2-44D4-9ABD-05376B97C26E

Q37319709-1A90EC8A-43E8-4FEB-90F8-DB16E2D7B2C2

Q37319709-221F67F1-5CF9-4360-823F-0D9BFA1E5501

Q37319709-2271DF3B-4E22-443E-AFDA-3A9F7E6E9E4B

Q37319709-330AB0BA-6935-4B77-8A08-489BF390E6BC

Q37319709-459AE951-056D-4A85-BA7A-084579666FA8

Q37319709-88B19C44-E7FC-43F3-81E6-450EB6C0966A

Q37319709-A08749BA-4A20-4231-8784-9CBEDDCAF972

Q37319709-D17CDE33-A2E4-4830-93AA-6A4B8112E550

Q37319709-EE79A17F-2CB3-47A9-9734-D2BAF0E30047

P2860

Q37319709-0C9FB6FC-5616-4FBE-B9B2-C0A0FEC25B3B

Q37319709-11453530-E463-4FFC-8719-51753980633A

Q37319709-195B68CA-87D6-4B48-A9FD-6B1B99BD8A4F

Q37319709-1CA65CA9-0D29-413E-ABC4-6DAE0F09ED5A

Q37319709-2FAFB06C-97EC-4064-98DB-F7FC172C25A4

Q37319709-34ED1CE7-12A9-4106-9A9F-702DB1D97ED9

Q37319709-37343B78-C944-4345-92A3-F7772CB58936

Q37319709-3A5950EA-4CD3-4F77-AC10-78A4A7F61168

Q37319709-43EED3A5-1CEE-4FE6-9EE8-636FCE9DC906

Q37319709-4BD9CFEE-0C48-49DF-B245-1D62F5EF358C

P304

Q37319709-B18FF649-FE32-4E9B-BA3B-5DE89030DE31

P31

Q37319709-3F22C212-FB7B-4012-851C-3D8C0429E966

P356

Q37319709-E8A0EF7E-5EDE-4337-B6E3-31BC66960A80

P407

Q37319709-8B2263C4-FF86-455D-B827-600408B47419

P433

Q37319709-7FD89F5F-4005-46E5-824B-E25A9D404E10

P478

Q37319709-8C065D02-D245-4032-AD32-F4EB4BDFA21D

P50

Q37319709-1F347259-3DEB-4EE4-A151-6522E039F4C9

Q37319709-83906F8F-994C-4D9F-AAA2-3D3795EC425D

Q37319709-AD620272-F28E-4D63-A3BB-2640420C840B

P577

Q37319709-64C64A5D-0711-44D6-A342-B4290A45F6A8

P5875

Q37319709-DEE576E7-AE42-4DBF-82A3-33AA9E15209D

P698

Q37319709-12DB9549-7362-4CEB-A864-D7C1388AD903

P921

Q37319709-5DC688D4-C5FA-462C-B63A-2A0596C55223

Q37319709-C13AB69F-E731-4184-A63A-E25D3918BC80

P932

Q37319709-80149EF8-18A8-4459-8C7F-2E5B15CB41D0

P356

PNAS.1303958110

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Enhancing tumor cell response ...... of siRNA and cisplatin prodrug

@en

P2093

Danica S Cui

http://www.w3.org/2001/XMLSchema#string

Eric M Pridgen

http://www.w3.org/2001/XMLSchema#string

Ga Young Park

http://www.w3.org/2001/XMLSchema#string

Jinjun Shi

http://www.w3.org/2001/XMLSchema#string

Jun Wu

http://www.w3.org/2001/XMLSchema#string

Kun Xie

http://www.w3.org/2001/XMLSchema#string

Robert Langer

http://www.w3.org/2001/XMLSchema#string

Stephen J Lippard

http://www.w3.org/2001/XMLSchema#string

Xiaoyang Xu

http://www.w3.org/2001/XMLSchema#string

Xue-Qing Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Suppression of Rev3, the catalytic subunit of Pol{zeta}, sensitizes drug-resistant lung tumors to chemotherapy

Structural basis of human DNA polymerase η-mediated chemoresistance to cisplatin.

Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans

Interactions of nanomaterials and biological systems: Implications to personalized nanomedicine

Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles

In vitro investigation on poly(lactide)-Tween 80 copolymer nanoparticles fabricated by dialysis method for chemotherapy.

REV3L confers chemoresistance to cisplatin in human gliomas: the potential of its RNAi for synergistic therapy

Lipid-like materials for low-dose, in vivo gene silencing

Variations on a theme: eukaryotic Y-family DNA polymerases

Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile.

P304

18638-18643

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1303958110

http://www.w3.org/2001/XMLSchema#string

P407

P433

46

http://www.w3.org/2001/XMLSchema#string

P478

110

http://www.w3.org/2001/XMLSchema#string

P50

Omid C. Farokhzad

Philip W. Kantoff

P577

2013-10-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258117615

http://www.w3.org/2001/XMLSchema#string

P698

24167294

http://www.w3.org/2001/XMLSchema#string

P921

P932

3832000

http://www.w3.org/2001/XMLSchema#string